Nursing Medical News about Diabetes Mellitus, Type 2 Vildagliptin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan
International Journal of Clinical Practice, 09/22/09

Devendra D et al. – During Ramadan, at least one hypoglycaemic event (defined as blood glucose < 3.5 mmol/l with or without symptoms) was recorded in two patients receiving vildagliptin (7.7%) and 16 patients receiving gliclazide. Vildagliptin was associated with a reduction in the mean number of hypoglycaemic events during Ramadan compared with before Ramadan, whereas gliclazide was associated with an increase. Both gliclazide and vildagliptin were associated with similar reductions in HbA1c and a small, but insignificant, increase in weight. Appropriate treatment adjustments can lead to improved diabetes management during Ramadan, with avoidance of significant weight gain and improved glucose control without hypoglycaemia. The addition of vildagliptin to metformin therapy during Ramadan in Muslim patients with type 2 diabetes was associated with a reduction in the incidence of hypoglycaemia.

<< Previous
Intensification with prandial insulin

Next >>
Failure after shockwave lithotripsy: is outcome machine...